Safety and tolerability results from a phase 2b, double-blind trial with an open-label extension of GH001 in treatment-resistant depression

Neuroscience Applied 2026 Open access

Read full text
Authors: B.T. Baune, N. Cardoner, F. Devlin, K. Doolin, RM Dueñas Herrero, M. Elices, M. Gałuszko Węgielnik, D. Gregory, L. Janů, J.R. Kelly, A. Kolos, S.J. McInerney
+10 more A. Nawka, T. Páleníček, V. Perez Sola, J.G. Ramaekers, Andreas Reif, MH Trivedi, V. Valcheva, Eduard Vieta, M.E. Thase, W.J. Cubała
DOI: 10.1016/j.nsa.2025.106573
Cited by: 1

Fields of Study & Subjects

Treatment of Major Depression Neurotransmitter Receptor Influence on Behavior Statistical Methods in Clinical Trials

Publication details

Journal / source
Neuroscience Applied
Publisher
Elsevier BV
Volume
5
Pages
106573–106573
Publication date
1 January 2026
Language
EN